Orgenesis Spotlighted in August 2012 Issue of Drug Discovery News
September 27 2012 - 7:00AM
Business Wire
Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a
development-stage company with a novel therapeutic technology
dedicated to converting a patient’s own liver cells into
functioning insulin-producing cells as a treatment for diabetes, is
one of several companies spotlighted in the August 2012 issue of
Drug Discovery News in a special report about regenerative
medicine.
The article, “Regenerating interest in stem cell medicine,”
reports that Orgenesis is focusing its efforts on treatment for
Type 1 diabetes. It notes that the company is concentrating on the
conversion of autologous liver cells into insulin-producing cells
that could be reimplanted in the liver to essentially replace the
missing functions of the pancreas. The article also reports that
Orgenesis, which is in the preclinical proof-of-concept phase, has
initiated conversations with regulators about proceeding to
clinical trial.
To read the article in its entirety, please visit the following
link:
http://www.drugdiscoverynews.com/index.php?newsarticle=6421
About Orgenesis Inc.
Orgenesis (ORGS) is a development stage company with a novel
therapeutic technology that employs a molecular and cellular
approach directed at converting a patient's own liver cells into
functional insulin producing cells, as a treatment for diabetes.
The Company believes that converting the diabetic patient's own
tissue into insulin-producing cells overcomes the problem of donor
shortage and removes the risk of transplant rejection. If
successful, this could mean the end of diabetes, as we now know it.
For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which
are not purely historical. Such forward-looking statements include,
among other things, the expectations of management that our
regeneration technology can be developed as therapeutic treatment
for diabetes. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if
they do occur, what benefits the Company will obtain from them.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with
new projects and development stage companies, which include,
without limitation, the potential failure of development candidates
to advance through preclinical studies or demonstrate safety and
efficacy in clinical testing and the ability to pass clinical
trials so as to move on to the next phase, our ability to retain
key employees and our ability to finance development or satisfy the
rigorous regulatory requirements for new medical procedures.
Competitors may develop better or cheaper alternatives to our
products. These forward-looking statements are made as of the date
of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Investors should refer to the risk factors disclosure
outlined in our periodic reports filed from time-to-time with the
Securities and Exchange Commission.
On Behalf of the BoardOrgenesis Inc.
Vered Caplan, Chairperson
Orgenesis (QX) (USOTC:ORGS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Orgenesis (QX) (USOTC:ORGS)
Historical Stock Chart
From Jan 2024 to Jan 2025
